Patents by Inventor Laura Alexandra Johnson

Laura Alexandra Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
    Patent number: 11865167
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 9, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada
  • CELL SECRETED MINIBODIES AND USES THEREOF
    Publication number: 20230357717
    Abstract: The present invention relates to compositions and methods for using a minibody. Minibodies described herein comprise a secretion signal, a variable heavy chain fragment, a variable light chain fragment, a constant chain fragment, and a hinge domain between the variable light chain fragment and the constant chain fragment. One aspect includes a nucleic acid encoding a minibody. Other aspects include compositions comprising a minibody and a modified T cell comprising a nucleic acid encoding a minibody. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy and treating a condition, such as cancer.
    Type: Application
    Filed: December 9, 2022
    Publication date: November 9, 2023
    Inventors: Laura Alexandra Johnson, Danielle Cook
  • Cell secreted minibodies and uses thereof
    Patent number: 11549099
    Abstract: The present invention relates to compositions and methods for using a minibody. Minibodies described herein comprise a secretion signal, a variable heavy chain fragment, a variable light chain fragment, a constant chain fragment, and a hinge domain between the variable light chain fragment and the constant chain fragment. One aspect includes a nucleic acid encoding a minibody. Other aspects include compositions comprising a minibody and a modified T cell comprising a nucleic acid encoding a minibody. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy and treating a condition, such as cancer.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: January 10, 2023
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Laura Alexandra Johnson, Danielle Cook
  • CELL SECRETED MINIBODIES AND USES THEREOF
    Publication number: 20200291354
    Abstract: The present invention relates to compositions and methods for using a minibody. Minibodies described herein comprise a secretion signal, a variable heavy chain fragment, a variable light chain fragment, a constant chain fragment, and a hinge domain between the variable light chain fragment and the constant chain fragment. One aspect includes a nucleic acid encoding a minibody. Other aspects include compositions comprising a minibody and a modified T cell comprising a nucleic acid encoding a minibody. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy and treating a condition, such as cancer.
    Type: Application
    Filed: March 23, 2017
    Publication date: September 17, 2020
    Inventors: Laura Alexandra Johnson, Danielle Cook
  • TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20190330356
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 31, 2019
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada
  • Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
    Patent number: 10308717
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: June 4, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, University of Pittsburgh—of The Commonwealth System of Higher Education
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada
  • TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20170008963
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Application
    Filed: June 15, 2016
    Publication date: January 12, 2017
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada
  • Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
    Patent number: 9394368
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 19, 2016
    Assignees: NOVARTIS AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada
  • TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20140322275
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 30, 2014
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada